Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
This study is currently recruiting participants.
Study NCT00527657 Information provided by M.D. Anderson Cancer Center
First Received: September 10, 2007 Last Updated: September 9, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Brain Neoplasms
Melanoma
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Central Nervous System Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Nervous System Diseases
Nervous System Neoplasms
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Interventions listed in this trial
Lomustine
Temozolomide
Thalidomide
More general drug interventions related to this trial
Alkylating Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Celgene Corporation
Back to top of Main Content
